A Phase Ib Study of TBio-4101 (Autologous Selected and Expanded Tumor-Infiltrating Lymphocytes [TIL]) and Pembrolizumab in Patients with Advanced Solid Tumor Malignancies (STARLING)
Details
A multicenter trial to investigate TBio-4101, an autologous, neoantigen-selected, tumor-reactive TIL product, in patients with advanced solid malignancies.
Eligibility
You can join if...
Inclusion Criteria
Patients with pathologically-confirmed, unresectable or metastatic solid tumors of one of the following: breast cancer, colorectal cancer, or uveal melanoma. Additional cohorts to be opened at sponsor discretion: cutaneous melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma
-Patients must be 18-70 years old, or beyond age 70 upon sponsor approval
Patient must be willing and able to undergo apheresis procedure
Exlcusion Criteria
Patients with a known additional malignancy that is progressing or has required active treatment within the past 3 years
Patients who have received prior cell therapy or prior organ transplant